Literature DB >> 25311898

Verbal episodic memory along the course of schizophrenia and bipolar disorder: a new perspective.

Letícia S Czepielewski1, Raffael Massuda1, Pedro Goi1, Miréia Sulzbach-Vianna1, Ramiro Reckziegel1, Monise Costanzi1, Flavio Kapczinski1, Adriane R Rosa2, Clarissa S Gama1.   

Abstract

Impairment on episodic memory (EM) has been strongly correlated with psychiatric disorders, including schizophrenia (SZ) and bipolar disorder (BD). Morevover, the effects of course and progression of the illness on cognitive functioning have not been well established. The aim of the present study is to assess performance of episodic memory in BD and SZ according to their clinical stages. Subjects who met DSM-IV criteria for bipolar disorder (n=43) and schizophrenia (31), on euthymia or clinical remission, were recruited from the outpatients facilities at Hospital de Clínicas de Porto Alegre (Brazil). They were classified into two clinical stages (early or late for BD, and recent onset or chronic for SZ) and compared to 54 healthy controls. Episodic memory performance was assessed by means the Hopkins Verbal Learning Test-Revised (HVLT-R) that measures verbal learning and episodic memory in both disorders. Our results showed that patients in early stage of BD (EBD) performed better performance on the total immediate free recall (p<0.0001, F=12.060) as well as in delayed free recall (p<0.0001, F=13.914) compared to late stage (LBD) and SZ groups. In the ability to retain words learned, LBD and chronic (CSZ) were more impaired than other groups. Furthermore, the variation of learning (i.e, learning effects) along the 3 trials of immediate free recall was similar between groups. In conclusion, we found a cognitive decline alongside with the progression of BD whereas such impairment was evident in the early of SZ. Despite this, both groups (BD and SZ) seem to maintain the ability to learn. It emphasizes the relevance of studying new therapeutic strategies, in particular, cognitive rehabilitation/remediation techniques as promissory treatment for psychiatric patients, even in those with moderate disabilities.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Cognitive dysfunction; Episodic memory; Schizophrenia

Mesh:

Year:  2014        PMID: 25311898     DOI: 10.1016/j.euroneuro.2014.09.006

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

1.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

2.  The association between lithium use and neurocognitive performance in patients with bipolar disorder.

Authors:  Katherine E Burdick; Caitlin E Millett; Manuela Russo; Martin Alda; Ney Alliey-Rodriguez; Amit Anand; Yokesh Balaraman; Wade Berrettini; Holli Bertram; Joseph R Calabrese; Cynthia Calkin; Carla Conroy; William Coryell; Anna DeModena; Scott Feeder; Carrie Fisher; Nicole Frazier; Mark Frye; Keming Gao; Julie Garnham; Elliot S Gershon; Kara Glazer; Fernando S Goes; Toyomi Goto; Gloria J Harrington; Petter Jakobsen; Masoud Kamali; Marisa Kelly; Susan Leckband; Else Marie Løberg; Falk W Lohoff; Adam X Maihofer; Michael J McCarthy; Melvin McInnis; Gunnar Morken; Caroline M Nievergelt; John Nurnberger; Ketil J Oedegaard; Abigail Ortiz; Megan Ritchey; Kelly Ryan; Martha Schinagle; Candice Schwebel; Martha Shaw; Paul Shilling; Claire Slaney; Emma Stapp; Bruce Tarwater; Peter Zandi; John R Kelsoe
Journal:  Neuropsychopharmacology       Date:  2020-04-29       Impact factor: 7.853

Review 3.  Neuroprogression and Cognitive Functioning in Bipolar Disorder: A Systematic Review.

Authors:  Taiane Cardoso; Isabelle E Bauer; Thomas D Meyer; Flavio Kapczinski; Jair C Soares
Journal:  Curr Psychiatry Rep       Date:  2015-09       Impact factor: 5.285

4.  Reduced Hippocampal Volume and Its Relationship With Verbal Memory and Negative Symptoms in Treatment-Naive First-Episode Adolescent-Onset Schizophrenia.

Authors:  Xujun Duan; Changchun He; Jianjun Ou; Runshi Wang; Jinming Xiao; Lei Li; Renrong Wu; Yan Zhang; Jingping Zhao; Huafu Chen
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

5.  The neurocognitive functioning in bipolar disorder: a systematic review of data.

Authors:  Eirini Tsitsipa; Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2015-12-01       Impact factor: 3.455

Review 6.  Immediate Early Genes, Memory and Psychiatric Disorders: Focus on c-Fos, Egr1 and Arc.

Authors:  Francisco T Gallo; Cynthia Katche; Juan F Morici; Jorge H Medina; Noelia V Weisstaub
Journal:  Front Behav Neurosci       Date:  2018-04-25       Impact factor: 3.558

Review 7.  Neurobiological underpinnings of bipolar disorder focusing on findings of diffusion tensor imaging: a systematic review.

Authors:  Juliana A Duarte; Jaisa Q de Araújo E Silva; André A Goldani; Raffael Massuda; Clarissa S Gama
Journal:  Braz J Psychiatry       Date:  2016-03-22       Impact factor: 2.697

8.  A clinical staging model for bipolar disorder: longitudinal approach.

Authors:  Lorena de la Fuente-Tomás; Pilar Sierra; Mónica Sanchez-Autet; Belén Arranz; Ana García-Blanco; Gemma Safont; Maria P García-Portilla
Journal:  Transl Psychiatry       Date:  2020-01-29       Impact factor: 6.222

Review 9.  Heterogeneous trajectories in schizophrenia: insights from neurodevelopment and neuroprogression models.

Authors:  Ramiro Reckziegel; Letícia S Czepielewski; Mathias Hasse-Sousa; Dayane S Martins; Maria J de Britto; Clara de O Lapa; Alexandre W Schwartzhaupt; Clarissa S Gama
Journal:  Braz J Psychiatry       Date:  2022 Jan-Feb       Impact factor: 2.697

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.